Bamrasnaradura Infectious Diseases Institute, Department of Diseases Control, Ministry of Public Health, Nonthaburi, Thailand.
Clin Exp Dermatol. 2022 Mar;47(3):573-577. doi: 10.1111/ced.14953. Epub 2021 Oct 24.
Favipiravir (FVP) has been used for treatment of COVID-19 in many countries. We analysed the incidence of FVP-induced cutaneous adverse reactions (CARs) in patients infected with COVID-19 who were hospitalized at Bamrasnaradura Infectious Diseases Institute, a principal centre of emerging infectious disease in Thailand, and who presented with cutaneous eruption following FVP prescription. We identified five cases of FVP-induced CARs: two patients with maculopapular rash, two with urticarial rash, and one with Stevens-Johnson syndrome. The median interval between FVP treatment and rash occurrence was 7 days and the mean duration of the rash was 5 days. This report highlights that FVP can induce CARs, particularly eruptions, in COVID-19-infected patients. Clinicians should be aware of this possible drug-related allergy, and it should be excluded as a cause of rash during FVP treatment of COVID-19.
法匹拉韦（FVP）已在许多国家用于治疗 COVID-19。我们分析了在泰国主要新发传染病中心巴姆拉纳德拉都拉传染病研究所因 COVID-19 住院且在使用 FVP 后出现皮疹的患者中 FVP 引起的皮肤不良反应（CARs）的发生率。我们确定了 5 例 FVP 诱导的 CARs：2 例患者出现斑丘疹，2 例患者出现荨麻疹样皮疹，1 例患者出现史蒂文斯-约翰逊综合征。FVP 治疗与皮疹发生之间的中位间隔为 7 天，皮疹的平均持续时间为 5 天。本报告强调，FVP 可引起 COVID-19 感染患者的 CARs，特别是皮疹。临床医生应意识到这种可能与药物相关的过敏反应，并在 COVID-19 治疗中使用 FVP 时应将其作为皮疹的原因排除。
